This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marimón, J. M.
Right arrow Articles by Pérez-Trallero, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marimón, J. M.
Right arrow Articles by Pérez-Trallero, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2004, p. 3789-3793, Vol. 48, No. 10
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.10.3789-3793.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Increasing Prevalence of Quinolone Resistance in Human Nontyphoid Salmonella enterica Isolates Obtained in Spain from 1981 to 2003

José M. Marimón,1 María Gomáriz,1 Carmen Zigorraga,2 Gustavo Cilla,1 and Emilio Pérez-Trallero1,3*

Servicio de Microbiología, Hospital Donostia,1 Laboratorio de Salud Publica,2 Departamento de Medicina Preventiva y Salud Pública, Universidad del País Vasco, San Sebastián, Spain3

Received 2 April 2004/ Returned for modification 23 May 2004/ Accepted 1 June 2004

From January 1981 to December 2003, susceptibility to nalidixic acid was tested in 10,504 nontyphoid Salmonella enterica isolates from patients with acute enteric disease in Gipuzkoa, Spain. The prevalence of nalidixic acid resistance steadily increased from less than 0.5% before 1991 to 38.5% in 2003, mainly due to the increase in resistance among isolates of the most prevalent serovar, S. enterica serovar Enteritidis. For nalidixic acid-resistant isolates, the ciprofloxacin MIC was eightfold higher than that for susceptible isolates, and the nalidixic acid-resistant isolates contained a single point mutation in the gyrA gene (at codons for Ser83 or Asp87). The same mutations were found in a sample of nalidixic acid-resistant nontyphoid Salmonella strains isolated between 1999 and 2003 from retail food for human consumption. In 2003, we identified five S. enterica serovar Typhimurium clinical isolates with high-level fluoroquinolone resistance (ciprofloxacin MIC, 16 µg/ml) with two point mutations in the gyrA gene (coding for Ser83->Phe and Asp87->Asn) and one point mutation in the parC gene (coding for Ser80->Arg). Strict sanitary controls are needed to avoid the spread of ciprofloxacin-resistant serovar Typhimurium isolates, and a more efficient veterinary policy must be adopted to decrease the large burden of Salmonella serovar Enteritidis infections in humans in our region.

* Corresponding author. Mailing address: Servicio de Microbiología, Hospital Donostia, Paseo Dr. Beguiristain s/n, 20014 San Sebastián, Spain. Phone: 34 94 300 7046. Fax: 34 94 300 7063. E-mail: mikrobiol{at}terra.es.

Antimicrobial Agents and Chemotherapy, October 2004, p. 3789-3793, Vol. 48, No. 10
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.10.3789-3793.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Soler, P., Gonzalez-Sanz, R., Bleda, M. J., Hernandez, G., Echeita, A., Usera, M. A. (2006). Antimicrobial resistance in non-typhoidal Salmonella from human sources, Spain, 2001-2003. J Antimicrob Chemother 58: 310-314 [Abstract] [Full Text]  
  • Murray, A., Coia, J. E., Mather, H., Brown, D. J. (2005). Ciprofloxacin resistance in non-typhoidal Salmonella serotypes in Scotland, 1993-2003. J Antimicrob Chemother 56: 110-114 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»